Table 2.
Clinical characteristics of bone marrow metastatic neuroblastoma patients according to MYCN and 11q23 statuses
| Variable | MYCN status [cases (%)] | P value* | 11q23 status [cases (%)] | P value* | ||
|---|---|---|---|---|---|---|
| Amplified | Normal | Deleted | Normal | |||
| Total | 12 | 89 | 40 | 61 | ||
| Sex | ||||||
| Male | 7 (58.3) | 50 (56.2) | 0.536 | 24 (60.0) | 33 (54.1) | 0.682 |
| Female | 5 (41.7) | 39 (43.8) | 16 (40.0) | 28 (45.9) | ||
| Age (months) | ||||||
| < 18 | 4 (33.3) | 12 (13.5) | 0.095 | 2 (5.0) | 14 (23.0) | 0.024 |
| ≥ 18 | 8 (66.7) | 77 (86.5) | 38 (95.0) | 47 (77.0) | ||
| Primary tumor site | ||||||
| Abdomen | 12 (100.0) | 76 (85.4) | 0.436 | 33 (82.5) | 55 (90.2) | 0.339 |
| Thorax | 0 (0) | 12 (13.5) | 6 (15.0) | 6 (9.8) | ||
| Neck | 0 (0) | 1 (1.1) | 1 (2.5) | 0 (0) | ||
| LDH (IU/L) | ||||||
| < 1500 | 1 (8.3) | 78 (87.6) | <0.001 | 32 (80.0) | 47 (77.0) | 0.808 |
| ≥ 1500 | 11 (91.7) | 11 (12.4) | 8 (20.0) | 14 (23.0) | ||
| NSE (ng/mL) | ||||||
| < 370 | 1 (8.3) | 59 (66.3) | < 0.001 | 21 (52.5) | 39 (63.9) | 0.302 |
| ≥ 370 | 11 (91.7) | 30 (33.7) | 19 (47.5) | 22 (36.1) | ||
| Event | ||||||
| No | 1 (8.3) | 48 (53.9) | 0.004 | 16 (40.0) | 33 (54.1) | 0.118 |
| Yes | 11 (91.7) | 41 (46.1) | 24 (60.0) | 28 (45.9) | ||
MYCN the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog, LDH lactate dehydrogenase, NSE neuron-specific enolase
* The χ2 test was used for statistical analysis